A Study to Evaluate the Safe and Effective Use of the Prefilled Safety Syringe or the Auto-injector for the Subcutaneous Self-injection of Bimekizumab Solution by Subjects With Active Psoriatic Arthritis
Public ClinicalTrials.gov record NCT04109976. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multicenter, Randomized, Open-Label Study to Evaluate the Safe and Effective Use of the Prefilled Safety Syringe or Auto-Injector for the Subcutaneous Self-Injection of Bimekizumab Solution by Subjects With Active Psoriatic Arthritis
Study identification
- NCT ID
- NCT04109976
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- UCB Biopharma SRL
- Industry
- Enrollment
- 214 participants
Conditions and interventions
Conditions
Interventions
- Bimekizumab Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 12, 2019
- Primary completion
- Nov 4, 2020
- Completion
- Nov 12, 2020
- Last update posted
- Nov 29, 2023
2019 – 2020
United States locations
- U.S. sites
- 20
- U.S. states
- 16
- U.S. cities
- 20
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Dv0004 50024 | Boise | Idaho | 83702 | — |
| Dv0004 50028 | Lexington | Kentucky | 40504 | — |
| Dv0004 50023 | Baton Rouge | Louisiana | 70836 | — |
| Dv0004 50015 | Hagerstown | Maryland | 21742 | — |
| Dv0004 50026 | Wheaton | Maryland | 20902 | — |
| Dv0004 50019 | Lansing | Michigan | 48910 | — |
| Dv0004 50016 | St Louis | Missouri | 63141 | — |
| Dv0004 50005 | Freehold | New Jersey | 07728 | — |
| Dv0004 50029 | Albuquerque | New Mexico | 87102 | — |
| Dv0004 50010 | Brooklyn | New York | 11201 | — |
| Dv0004 50125 | Charlotte | North Carolina | 28210 | — |
| Dv0004 50031 | Salisbury | North Carolina | 28144 | — |
| Dv0004 50040 | Dayton | Ohio | 45417 | — |
| Dv0004 50020 | Duncansville | Pennsylvania | 16635 | — |
| Dv0004 50006 | Wyomissing | Pennsylvania | 19610 | — |
| Dv0004 50008 | Johnston | Rhode Island | 02919 | — |
| Dv0004 50001 | Jackson | Tennessee | 38305 | — |
| Dv0004 50036 | Mesquite | Texas | 75150 | — |
| Dv0004 50009 | Waco | Texas | 76710 | — |
| Dv0004 50050 | Beckley | West Virginia | 25801 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 27 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04109976, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 29, 2023 · Synced May 12, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04109976 live on ClinicalTrials.gov.